Preclinical literature describes effects involving nitric-oxide signalling, VEGF/VEGFR2-linked angiogenic pathways, fibroblast migration, growth-factor signalling and inflammatory mediators. These are mechanistic hypotheses from laboratory and animal work, not established clinical effects in humans.

A 2025 systematic review of musculoskeletal literature found 35 preclinical studies and only one small clinical study. The human report was uncontrolled and involved 12 people with chronic knee pain, so it cannot establish efficacy or safety. A 2026 development review similarly concludes that clinical development remains rudimentary and that standardized pharmacokinetics, formulations and controlled trials are missing.

Animal studies span tendon, ligament, muscle, bone, gastrointestinal and vascular models. Reported improvements in structural or functional outcomes are hypothesis-generating, but translation from rodent injury models to human disease is uncertain.

• No completed Phase II programme or large randomized controlled trials were identified.
• Human safety data are sparse; manufacturing quality and peptide-related impurities are separate risks from the molecule itself.
• Findings from animal models should not be presented as proven human healing or recovery benefits.

Full-length thymosin β4 is an endogenous actin-sequestering peptide involved in cell migration and tissue-repair signalling. Literature describes angiogenic, anti-inflammatory and anti-apoptotic effects in experimental systems. Commercial “TB-500” products may be fragments or related peptides, so molecular equivalence to full-length Tβ4 must not be assumed.

Clinical research exists for full-length thymosin β4 in areas such as dermal wound healing, including small phase 2 programmes. However, recent sports-medicine reviews emphasize that human musculoskeletal evidence for TB-500 itself is lacking. Results from Tβ4 studies therefore provide biological context rather than direct proof for a TB-500 preparation.

Preclinical models report effects on migration, angiogenesis and tissue repair. These studies are useful for pathway research, but fragment identity, formulation and route can materially affect whether findings are relevant to a given research product.

• TB-500 and full-length thymosin β4 should be distinguished in scientific copy.
• Human orthopaedic efficacy data are lacking.
• Antidoping restrictions apply to thymosin-related growth-factor/modulating substances in competitive sport.

GHK binds copper(II) and has been investigated for effects on extracellular-matrix turnover, collagen and glycosaminoglycan synthesis, metalloproteinase regulation, fibroblast activity, oxidative stress and wound-related signalling.

Some cosmetic and topical literature reports changes in skin appearance or matrix markers, but modern reviews highlight a surprising shortage of rigorous clinical studies and unanswered questions around skin permeability and formulation. Recent sports-medicine reviews find no convincing clinical evidence for injectable musculoskeletal use.

Cell and animal work is extensive relative to human trials and includes wound-healing, fibroblast, collagen, inflammatory and tissue-remodelling models. This supports biological plausibility but not broad clinical claims.

• Topical/cosmetic evidence should not be extrapolated to injectable research formats.
• Published formulations differ; copper complexation and delivery conditions can influence activity.
• Clinical efficacy and long-term safety for systemic use remain uncertain.

MOTS-c is encoded within mitochondrial DNA and has been linked to cellular stress responses, AMPK-associated metabolic signalling and mitochondria-to-nucleus communication. It is often discussed as a mitokine or mitochondrial-derived signalling peptide.

Human studies show that endogenous MOTS-c can change with exercise. A 2021 Nature Communications study measured increases in skeletal-muscle and circulating MOTS-c after exercise in healthy volunteers. This demonstrates physiological association, not that exogenous MOTS-c treatment reproduces exercise benefits in people. A 2026 systematic review of mitochondrial-derived peptides and exercise described the human evidence base as small and heterogeneous.

Mouse studies report effects on physical capacity, metabolic adaptation, insulin sensitivity and stress responses. These findings underpin current research interest but are not equivalent to proven outcomes in humans.

• Endogenous exercise-induced MOTS-c is not the same evidence question as administering synthetic MOTS-c.
• Controlled human intervention trials remain sparse.
• Assay methods and measured circulating concentrations vary across studies.

Retatrutide is designed to agonize GIP, GLP-1 and glucagon receptors. The programme studies how combined incretin and glucagon-receptor signalling affects energy balance, glycaemia, appetite and body weight.

A peer-reviewed 2023 phase 2 randomized trial in 338 adults with obesity reported substantial mean weight reductions over 48 weeks and established the basis for phase 3 testing. By 2026, Lilly had announced positive phase 3 topline results from multiple TRIUMPH studies, including obesity populations with and without type 2 diabetes and cardiovascular disease. Full peer-reviewed publication of every phase 3 dataset may lag company topline announcements.

Mechanistic and preclinical work informed receptor selection and metabolic hypotheses, but the most decision-relevant evidence is now from randomized human trials.

• Retatrutide remains investigational; it should not be represented as an approved medicine.
• Topline company announcements are less complete than full peer-reviewed trial reports.
• Safety/tolerability findings need to be interpreted within controlled clinical trials, not extrapolated to unregulated products.

Tirzepatide is a peptide agonist at GIP and GLP-1 receptors. Its pharmacology influences glucose-dependent insulin secretion, appetite/energy intake and metabolic regulation.

SURMOUNT-1 was a large phase 3 randomized trial in 2,539 adults with obesity or overweight without diabetes and demonstrated clinically substantial weight reduction over 72 weeks versus placebo. Tirzepatide also has extensive type 2 diabetes trial data. NICE guidance recognizes tirzepatide (Mounjaro) for managing overweight/obesity and type 2 diabetes in defined NHS populations.

Preclinical receptor pharmacology helped establish the rationale for dual GIP/GLP-1 agonism, but the compound now has extensive human clinical evidence and regulatory review.

• Evidence for licensed tirzepatide does not establish quality, safety or equivalence of an unlicensed research preparation.
• Clinical benefits and risks come from controlled pharmaceutical-grade products used under regulated conditions.
• The research library does not provide treatment or prescribing guidance.

CJC-1295 was developed as a long-acting analogue of growth-hormone-releasing hormone (GHRH). Ipamorelin is a growth-hormone secretagogue acting through the ghrelin/GHS receptor pathway. Both can stimulate GH release through different upstream mechanisms, which explains research interest in combined signalling.

A 2006 randomized study of CJC-1295 in healthy adults reported prolonged increases in GH and IGF-1 following the defined investigational analogue. A human PK/PD study of ipamorelin showed a short terminal half-life and a discrete GH-release response. Ipamorelin was also tested in a randomized postoperative-ileus study, where the primary efficacy endpoint was not statistically significant. These studies do not establish efficacy of a retail CJC + ipamorelin blend.

Animal and mechanistic studies explore muscle, endocrine and GH-axis endpoints. Recent reviews describe combination-specific evidence as largely preclinical.

• “CJC” products may differ in analogue/formulation; evidence on one CJC-1295 study compound cannot automatically be generalized.
• Human studies of the two components separately do not validate a fixed-ratio combination.
• Long-term safety and clinically meaningful outcomes for this blend are not established.

NAD+ (nicotinamide adenine dinucleotide) cycles between oxidized and reduced states in core metabolic pathways and also serves as a substrate for enzymes including sirtuins, PARPs and CD38-related pathways. Ageing and disease-related changes in NAD metabolism are an active research field.

Most modern human intervention evidence concerns NAD+-boosting precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), not direct administration of NAD+ itself. Reviews find that precursor supplementation can raise NAD-related metabolites, but consistent improvements in clinical function or “anti-ageing” outcomes have not been established across populations. A 2025 Nature Metabolism review describes human efficacy as limited and tissue-specific evidence as sparse.

Rodent and cell studies report broad metabolic, mitochondrial, inflammatory and stress-response effects from manipulating NAD metabolism. Translation is complicated because different precursors, tissues and disease states produce different responses.

• Do not treat NR/NMN trial results as direct evidence for an NAD+ research preparation.
• “Anti-ageing” claims run ahead of the current clinical evidence.
• Optimal route, exposure, long-term safety and clinically meaningful endpoints remain active research questions.

KLOW combines four compounds with different proposed research pathways: GHK-Cu (copper/matrix signalling), BPC-157 (preclinical repair and nitric-oxide/angiogenic pathways), TB-500/thymosin-related signalling (actin/cell migration context) and KPV (an α-MSH-derived tripeptide investigated for anti-inflammatory signalling). There is no scientific basis to assume the effects of the components simply add together.

No controlled human study of the KLOW blend was identified. Human evidence for BPC-157, TB-500 and GHK-Cu is limited or indirect, while KPV evidence is predominantly cellular and animal. Any claims about the blend therefore need to remain explicitly exploratory.

KPV has been investigated in intestinal epithelial/immune-cell systems and mouse colitis models, including effects involving PepT1 uptake and inflammatory signalling. The other three components have separate preclinical literatures summarized elsewhere in this library.

• No blend-specific pharmacokinetic, interaction or safety studies were identified.
• Component findings cannot be summed to predict efficacy or safety of the combination.
• TB-500/full-length thymosin β4 identity caveats remain relevant inside the blend.